(OVIT.OB) OncoVista Issued $16 Price Target From Status Equity Research

SOURCE:

IO News Wire

2008-08-21 13:58:00

(OVIT.OB) OncoVista Issued $16 Price Target From Status Equity Research

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY–(EMWNews – August 21, 2008) – OncoVista Innovative Therapies, Inc. (OTCBB: OVIT) is a biopharmaceutical company engaged in the development and

commercialization of targeted cancer therapies and diagnostics.

According to the Status Equity Research report published August 12, 2008,

the world market for in vitro diagnostic (IVD) tests for cancer is growing

at 11% annually and could reach $8 billion by the end of 2012.

Status concludes that a successful market launch and penetration of OVIT’s

AdnaTest, can yield $80 million in first year, post launch sales in the

U.S. in 2010.

The research report can be accessed at STATUS EQUITY RESEARCH REPORT — OVIT

Other active stocks are Johnson & Johnson (NYSE: JNJ); Novartis AG (NYSE: NVS); Sanofi-Aventis (NYSE: SNY).

For More Information on OncoVista Innovative Therapies, Inc. please visit:

www.oncovista.com.

For More Information on Status Equity Research please visit:

www.statusequity.com.

About Status Equity Research

Status Equity Research is a monthly publication committed to providing

coverage on unique emerging growth companies that can become sector leaders

in the U.S. equity markets.

About OncoVista, Inc.

OncoVista is a biopharmaceutical company engaged in the development and

commercialization of targeted cancer therapies both through the acquisition

of rights to technologies and drugs from others and through the development

of proprietary products. OncoVista focuses on candidates that have been

previously tested in human clinical trials or animal models, as well as

technologies that may improve the delivery or targeting of previously

tested, and in some cases marketed, anticancer agents.

Information, opinions and analysis contained herein are based on sources

believed to be reliable, but no representation, expressed or implied, is

made as to its accuracy, completeness or correctness. The opinions

contained herein reflect our current judgment and are subject to change

without notice. We accept no liability for any losses arising from an

investor’s reliance on or use of this report. This report is for

information purposes only, and is neither a solicitation to buy nor an

offer to sell securities. A third party has hired and paid IO News Wire

$2,495.00 for the publication and circulation of this news release. Certain

information included herein is forward-looking within the meaning of the

Private Securities Litigation Reform Act of 1995, including, but not

limited to, statements concerning manufacturing, marketing, growth, and

expansion. Such forward-looking information involves important risks and

uncertainties that could affect actual results and cause them to differ

materially from expectations expressed herein. We have no ownership of

equity, no representation do no trading of any kind and send No Faxes or

emails.

Contact:
WB
Company: IONEWSWIRE.COM
Phone: 1(516) 942-4910

free cash grants, free grant money, free money, cash grants, scholarships, business grants, foundation grants, government grants, debt grants, consolidation, college tuition, financial aid, medical grants, personal grants, medical bills, unsecured loans, no interest loans, financing, loans, capital, non profit organizations

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions